Search

everythinglearnresearchcommunity

for

Search:↓

Baricitinib for severe alopecia areata is generally safe, with common side effects like infections and acne, and low rates of serious complications.

Ruxolitinib can cause a delayed skin reaction on the nose.

Baricitinib is effective and cost-efficient for treating severe alopecia areata in adults.

Biologics and targeted therapies could improve treatment for children with certain chronic skin conditions.

Erosive pustular dermatosis of the scalp can occur about 17 weeks after starting EGFR inhibitors, and early minocycline may help manage it.

Agalsidase alfa helps treat Fabry's disease but needs more research for long-term benefits.

Tofacitinib helped some young children with severe hair loss grow their hair back without bad side effects.

Trodelvy™ helped some patients with advanced breast cancer, but had side effects.

Long-term data and a team approach are needed to manage chronic side effects from cancer treatments.

Tofacitinib helped psoriasis but not alopecia universalis, needing more research.

Dupilumab can both improve and worsen alopecia areata, with higher IgE levels linked to better outcomes.

A patient with alopecia areata regrew hair after taking tofacitinib and showed changes in certain blood and skin markers.

Getting insurance to cover the hair loss treatment tofacitinib is hard because it's not officially approved for that use.

Tofacitinib successfully treated hair loss in a Crohn's disease patient who previously used adalimumab.

Tofacitinib may be an effective and safe treatment for adolescent alopecia areata.

Some drugs, especially biologics, can cause skin reactions that look like other skin diseases, and stopping the drug usually helps clear up these reactions.

A young boy with Netherton syndrome improved significantly using IVIG, dupilumab, and dietary changes.

Upadacitinib may effectively treat both alopecia universalis and Crohn's disease.

Amivantamab can cause severe skin eruptions and scarring, requiring drug discontinuation and early treatment.

CS12192 effectively treats alopecia areata with better safety than current options.

Teriflunomide effectively reduces relapse rates and disease progression in multiple sclerosis but is not safe for use during pregnancy.

Janus kinase inhibitors are effective for severe alopecia areata, promoting hair regrowth.

Fish oil increased cell growth and macrophages in the skin but didn't affect COX-2 expression.

Tofacitinib effectively treated both ulcerative colitis and alopecia areata in two patients.

JAK inhibitors may help treat alopecia areata and promote hair regrowth.

Ritlecitinib effectively treats alopecia areata in patients 12 and older with fewer side effects.

Tofacitinib helped most patients with alopecia areata regrow hair and changes in immune cells were linked to the treatment's effectiveness.

Baricitinib at 2mg and 4mg doses improved work productivity and reduced costs for adults with atopic dermatitis.

Abrocitinib may help treat alopecia areata effectively with mild side effects.

Ruxolitinib helped a woman with a genetic mutation regrow her hair and improved her health.